1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023

IF 6.2 1区医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes Pub Date : 2024-07-19 DOI:10.2337/db24-1073-p

KARA R. MIZOKAMI-STOUT, LAUREN OSHMAN, HEIDI L. DIEZ, DINA H. GRIAUZDE, JOYCE M. LEE, KATHERINE L. KHOSROVANEH, NEHA BHOMIA, NOA KIM, JACQUELINE RAU, JACOB REISS, RODICA BUSUI

{"title":"1073-P: Trends in Guideline-Directed Medication Therapy for Type 2 Diabetes in a Statewide Quality Collaborative between 2018–2023","authors":"KARA R. MIZOKAMI-STOUT, LAUREN OSHMAN, HEIDI L. DIEZ, DINA H. GRIAUZDE, JOYCE M. LEE, KATHERINE L. KHOSROVANEH, NEHA BHOMIA, NOA KIM, JACQUELINE RAU, JACOB REISS, RODICA BUSUI","doi":"10.2337/db24-1073-p","DOIUrl":null,"url":null,"abstract":"Introduction and Objective: Since 2021, the Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve guideline-directed medication therapies (GDMT) for type 2 diabetes (T2D). We examined trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose transport protein 2 inhibitor (SGLT2i) prescribing rates comparing primary care (PC) and endocrinology (Endo) practices enrolled in MCT2D. Methods: We analyzed pharmacy claims data from adults with T2D insured by Blue Cross Blue Shield of Michigan Preferred Provider Organization and Medicare Advantage plans who received care in an MCT2D-participating practice (PC=300; Endo=19) between 2018-2023. Descriptive statistics were used to examine differences in pharmacy claims for anti-hyperglycemic medications. Results: From June 2022-June 2023, among 38,437 persons with T2D (PC=37,361; Endo=1,076), 26% and 41% had claims for GLP-1RA and 19% and 37% for SGLT2i, respectively. Compared to 2018 prescription rates, GLP-1RA increased by 17% and 22%, while SGLT2i prescriptions increased by 15% and 28% in PC and Endo practices respectively (Figure 1). Conclusion: Among practices participating in a statewide collaborative to improve treatment and outcomes for people with T2D, the use of GDMT has increased since 2018. SGLT2i use is similar and GLP-1RA use is 2-3-fold higher than rates reported in other studies. Disclosure K.R. Mizokami-Stout: None. L. Oshman: Stock/Shareholder; Procter & Gamble, Johnson & Johnson Medical Devices Companies, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Abbott. H.L. Diez: None. D.H. Griauzde: None. J.M. Lee: Board Member; GoodRx. Advisory Panel; Sanofi. Consultant; Tandem Diabetes Care, Inc. K.L. Khosrovaneh: None. N. Bhomia: None. N. Kim: None. J. Rau: None. J. Reiss: None. R. Busui: Board Member; American Diabetes Association. Consultant; Procter & Gamble, AstraZeneca, Averitas Pharma, Inc., Bayer Inc., Lexicon Pharmaceuticals, Inc., Nevro Corp., Ono Pharmaceutical Co., Ltd., Novo Nordisk, Roche Diagnostics. Advisory Panel; ADA/ACC Diabetes by Heart Program.","PeriodicalId":11376,"journal":{"name":"Diabetes","volume":"92 1","pages":""},"PeriodicalIF":6.2000,"publicationDate":"2024-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2337/db24-1073-p","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction and Objective: Since 2021, the Michigan Collaborative for Type 2 Diabetes (MCT2D) aims to improve guideline-directed medication therapies (GDMT) for type 2 diabetes (T2D). We examined trends in glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose transport protein 2 inhibitor (SGLT2i) prescribing rates comparing primary care (PC) and endocrinology (Endo) practices enrolled in MCT2D. Methods: We analyzed pharmacy claims data from adults with T2D insured by Blue Cross Blue Shield of Michigan Preferred Provider Organization and Medicare Advantage plans who received care in an MCT2D-participating practice (PC=300; Endo=19) between 2018-2023. Descriptive statistics were used to examine differences in pharmacy claims for anti-hyperglycemic medications. Results: From June 2022-June 2023, among 38,437 persons with T2D (PC=37,361; Endo=1,076), 26% and 41% had claims for GLP-1RA and 19% and 37% for SGLT2i, respectively. Compared to 2018 prescription rates, GLP-1RA increased by 17% and 22%, while SGLT2i prescriptions increased by 15% and 28% in PC and Endo practices respectively (Figure 1). Conclusion: Among practices participating in a statewide collaborative to improve treatment and outcomes for people with T2D, the use of GDMT has increased since 2018. SGLT2i use is similar and GLP-1RA use is 2-3-fold higher than rates reported in other studies. Disclosure K.R. Mizokami-Stout: None. L. Oshman: Stock/Shareholder; Procter & Gamble, Johnson & Johnson Medical Devices Companies, Merck & Co., Inc., AbbVie Inc., Eli Lilly and Company, Abbott. H.L. Diez: None. D.H. Griauzde: None. J.M. Lee: Board Member; GoodRx. Advisory Panel; Sanofi. Consultant; Tandem Diabetes Care, Inc. K.L. Khosrovaneh: None. N. Bhomia: None. N. Kim: None. J. Rau: None. J. Reiss: None. R. Busui: Board Member; American Diabetes Association. Consultant; Procter & Gamble, AstraZeneca, Averitas Pharma, Inc., Bayer Inc., Lexicon Pharmaceuticals, Inc., Nevro Corp., Ono Pharmaceutical Co., Ltd., Novo Nordisk, Roche Diagnostics. Advisory Panel; ADA/ACC Diabetes by Heart Program.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

1073-P：2018-2023 年间全州质量协作组织 2 型糖尿病指南指导下的药物治疗趋势

导言和目标：自 2021 年起，密歇根 2 型糖尿病合作组织（MCT2D）旨在改进 2 型糖尿病（T2D）的指导性药物疗法（GDMT）。我们研究了胰高血糖素样肽-1 受体激动剂 (GLP-1RA) 和钠-葡萄糖转运蛋白 2 抑制剂 (SGLT2i) 的处方率趋势，并对加入 MCT2D 的初级保健 (PC) 和内分泌 (Endo) 诊所进行了比较。方法：我们分析了密歇根州蓝十字蓝盾首选提供商组织和医疗保险优势计划投保的 T2D 成人的药房索赔数据，这些成人在 2018-2023 年期间在参与 MCT2D 的诊所（PC=300；Endo=19）接受了治疗。描述性统计用于研究抗高血糖药物的药房索赔差异。结果：从 2022 年 6 月到 2023 年 6 月，在 38,437 名 T2D 患者中（PC=37,361；Endo=1,076），分别有 26% 和 41% 的患者报销了 GLP-1RA 和 19% 和 37% 的 SGLT2i。与 2018 年的处方率相比，PC 和 Endo 诊所的 GLP-1RA 处方分别增加了 17% 和 22%，而 SGLT2i 处方分别增加了 15% 和 28%（图 1）。结论在参与旨在改善 T2D 患者治疗和疗效的全州合作项目的医疗机构中，GDMT 的使用自 2018 年以来有所增加。与其他研究报告的比例相比，SGLT2i 的使用情况类似，GLP-1RA 的使用率高出 2-3 倍。披露 K.R. Mizokami-Stout：无。L. Oshman：宝洁公司、强生公司、默克公司、艾伯维公司、礼来公司、雅培公司的股票/股东。H.L. Diez：无。D.H. Griauzde：无。J.M. Lee：董事会成员；GoodRx。顾问团；赛诺菲。顾问；Tandem Diabetes Care, Inc.K.L. Khosrovaneh：无。N. Bhomia：无。N. Kim：无。J. Rau：无。J. Reiss：无。R. Busui：美国糖尿病协会董事会成员。顾问；宝洁公司、阿斯利康公司、Averitas 制药公司、拜耳公司、Lexicon 制药公司、Nevro 公司、Ono 制药有限公司、诺和诺德公司、罗氏诊断公司。ADA/ACC 糖尿病心脏计划顾问团。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes 医学-内分泌学与代谢

CiteScore

12.50

自引率

2.60%

发文量

1968

审稿时长

1 months

期刊介绍： Diabetes is a scientific journal that publishes original research exploring the physiological and pathophysiological aspects of diabetes mellitus. We encourage submissions of manuscripts pertaining to laboratory, animal, or human research, covering a wide range of topics. Our primary focus is on investigative reports investigating various aspects such as the development and progression of diabetes, along with its associated complications. We also welcome studies delving into normal and pathological pancreatic islet function and intermediary metabolism, as well as exploring the mechanisms of drug and hormone action from a pharmacological perspective. Additionally, we encourage submissions that delve into the biochemical and molecular aspects of both normal and abnormal biological processes. However, it is important to note that we do not publish studies relating to diabetes education or the application of accepted therapeutic and diagnostic approaches to patients with diabetes mellitus. Our aim is to provide a platform for research that contributes to advancing our understanding of the underlying mechanisms and processes of diabetes.